Key Highlights

  • Net loss was USD 2.6 million, or USD 0.49 per diluted share.
  • Cash was USD 9.7 million, compared with USD 7.6 million at year-end 2025.
  • Research and development expenses were USD 1.1 million, up USD 0.7 million.
  • The company raised about USD 1.5 million through its Equity line during the quarter.

Acurx Pharmaceuticals (NASDAQ:ACXP) reported a third-quarter 2026 net loss of USD 2.6 million, or USD 0.49 per diluted share, against USD 2 million, or USD 1.23 per share, in the prior-year quarter. The Earnings table shows an estimate of a USD 0.38 loss per share. The company is a clinical-stage biopharmaceutical company developing a new class of antibiotics for bacteria on the priority pathogen lists of the World Health Organization, the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration.

The company reported no Revenue for the period. It had 5.88 million shares outstanding as of September 30, 2026.

Spending and Net Loss

Research and development expenses were USD 1.1 million for the three months ended September 30, 2026, against USD 0.4 million in the prior-year quarter, an increase of USD 0.7 million. For the nine months, Research and Development expenses were USD 2.5 million, against USD 1.6 million.

General and administrative expenses were USD 1.5 million for the quarter, against USD 1.6 million a year earlier. For the nine months, they were USD 4.1 million, against USD 4.9 million, a decrease of USD 0.8 million. Management cited a decrease of USD 0.1 million in compensation-related expenses and a change in legal costs.

Net loss was USD 6.5 million for the nine months ended September 30, 2026, against USD 6.4 million a year earlier, or USD 1.59 per diluted share against USD 5.01. The net loss for the year ended December 31, 2025 was USD 8.0 million.

Cash, Funding and Going Concern Disclosure

The company ended the quarter with cash of USD 9.7 million, compared with USD 7.6 million as of December 31, 2025. During the quarter, it raised approximately USD 1.5 million of gross proceeds through its equity line of credit. As of September 30, 2026, Working Capital was USD 7.3 million. That consisted mainly of USD 9.7 million of cash and USD 0.6 million of prepaid expenses, offset by approximately USD 3.0 million of Accounts Payable and accrued expenses.

Net loss exceeded net cash used in Operating Activities by USD 0.9 million. The filing attributes this to share-based compensation and share-based vendor payments of USD 0.9 million and an increase in accounts payable and accrued expenses of USD 0.6 million, offset by an increase in prepaid expenses of USD 0.6 million.

The filing states that these matters raise substantial doubt about the company's ability to continue as a going concern. It notes that the financial statements do not include any adjustments that might result from the outcome of that uncertainty. Earlier funding listed in the filing includes IPO net proceeds of approximately USD 14.8 million in June 2021 and net proceeds of approximately USD 3.5 million from a May 2023 registered direct offering and concurrent private placement.

The Ibezapolstat Program and Reported Reference Points

The filing describes ibezapolstat as the first antibiotic candidate to work by blocking the DNA pol IIIC enzyme in C. difficile, an enzyme required for DNA replication in certain Gram-positive bacteria. The company also has an early-stage pipeline that includes ACX 375C, a potential oral and parenteral treatment targeting Gram-positive bacteria including MRSA, VRE and PRSP, and B. anthracis.

The filing says Phase 2a data showed complete eradication of colonic C. difficile by day three of treatment with ibezapolstat, along with overgrowth of healthy gut microbiota. It also references a Phase 3 non-inferiority framework against vancomycin, in line with FDA guidance dated May 2026.

The reported items for the quarter are a net loss of USD 2.6 million, research and development expenses of USD 1.1 million, cash of USD 9.7 million and the equity line proceeds of about USD 1.5 million. The company is listed on the Nasdaq Capital Market.